Objetivo Antibiotics are routinely used in the treatment of lung microbial infections and there is concern about the increasing number of lung pathogens which show antibiotic-resistance. Lung surfactant proteins A and D (SP-A and SP-D) are part of the naturally occurring innate immune system which provides an immediate defence against a wide range of lung pathogens (viruses, bacteria and fungi) and also have an anti-inflammatory forms of allergic reactions. Levels of SP-A -and SP-D fall during certain infections. thus the use of recombinant forms of these proteins may alleviate the need for administration of antibiotics, especially in the very young, ventilated patients and immunocompromised adults (such as AIDS patients). Recombinant forms of SP-A and SP-D will be directly tested as therapeutic agents and also after their addition to lung surfactant preparations which are in clinical use/or trials (which at present lack SP-A and SP-D). The recombinant forms of SP-A and SP-D will be fully characterised and their biological properties assessed by in vitro assays and in animal models of lung infection and inflammation. This will allow the formulation of the optimal recombinant forms of SP-A and SP-D for use in human clinical trials. Ámbito científico natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programa(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Tema(s) 1.1.1.-2. - Key action Control of Infectious Diseases Convocatoria de propuestas Data not available Régimen de financiación CSC - Cost-sharing contracts Coordinador Medical Research Council (MRC) Aportación de la UE Sin datos Dirección 20 Park Crescent W1N 4AL London Reino Unido Ver en el mapa Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo ALTANA PHARMA A.G. Alemania Aportación de la UE Sin datos Dirección Byk-Gulden Str. 2 78467 KONSTANZ Ver en el mapa Coste total Sin datos UNIVERSIDAD COMPLUTENSE DE MADRID España Aportación de la UE Sin datos Dirección Ciudad Universitaria s/n 28040 MADRID Ver en el mapa Coste total Sin datos UNIVERSITY OF SOUTHERN DENMARK - UNIVERSITY OF ODENSE Dinamarca Aportación de la UE Sin datos Dirección Winsloeevparken 21 5000 ODENSE Ver en el mapa Coste total Sin datos UTRECHT UNIVERSITY Países Bajos Aportación de la UE Sin datos Dirección Yalelaan 1 3584 CL UTRECHT Ver en el mapa Coste total Sin datos
